Goldberg Law PC (www.Goldberglawpc.com) announces that a class action lawsuit has been filed against Chiasma, Inc. ("Chiasma" or the "Company") (Nasdaq: CHMA). Investors who purchased or otherwise acquired shares between July 15, 2015 and April 17, 2016 (the “Class Period”), are encouraged to contact the firm in advance of the August 8, 2016 lead plaintiff motion deadline.

If you are a shareholder who suffered a loss during the Class Period, click here to participate. In addition, we advise you to contact Michael Goldberg or Brian Schall, of Goldberg Law PC, 1999 Avenue of the Stars, Suite 1100, Los Angeles, CA 90067, at 800-977-7401, to discuss your rights without cost to you. You can also reach us through the firm’s website at http://www.Goldberglawpc.com, or by email at info@goldberglawpc.com.

The class in this case has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.

According to the complaint, Chiasma made materially false and/or misleading statements and/or failed to disclose: that the Phase 3 clinical trial for its oral octreotide, Mycapssa, which was conducted before the July 15, 2015 IPO, was insufficient to prove efficacy and secure FDA approval; that Chiasma’s supervision of its suppliers was not sufficient enough to prevent deficiencies that delayed FDA approval of Mycapssa; and as a result of the above, the Company’s public statements were materially false and misleading at all relevant times. On April 18, 2016 the Company announced that the FDA issued a Complete Response Letter in response to the Company’s New Drug Application for Mycapssa stating that the FDA did not believe the application provided sufficient evidence of efficacy to warrant approval, another clinical trial would be necessary, and that deficiencies with the Company’s suppliers would need to be resolved. When Chiasma announced this news on April 18, 2016 the share price fell 63.13% on that day.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.